Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880357 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 485
- Enrollment target
NCT03880357: Completed Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT03880357 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 485 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (708% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03880357, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 485 participants
- Enrollment target
Study Summary
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of scalp psoriasis.
Primary Outcome
The proportion of subjects in each treatment group with "treatment success" (defined as none or minimal, a score of 0 or 1, within the treatment area) on the PGA of disease severity
Interventions
- DRUG Taclonex®
- DRUG Betamethasone Scalp Suspension 0.064%;0.0005%
- DRUG Placebo topical suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 1 |
What the finished NCT03880357 record still lists
NCT03880357 is an interventional study that assigns participants to a tested intervention. The registered 485 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (708% higher).
The record links to 0 conditions, and to 3 interventions - of which Taclonex® is the first listed.
NCT03880357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03880357 about?
NCT03880357 is a clinical study titled "To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis". To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of scalp psoriasis.
What is the current status of trial NCT03880357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 485 participants. The study started on 2018-10-22. Estimated completion is 2019-03-15.
What interventions are being tested in trial NCT03880357?
The interventions under investigation include: Taclonex® (DRUG), Betamethasone Scalp Suspension 0.064%;0.0005% (DRUG), Placebo topical suspension (DRUG).
Who is sponsoring clinical trial NCT03880357?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03880357's enrollment target sits among peer trials
485 48th of 2000 higher than 1,953 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI